The multiple myelomas - current concepts in cytogenetic classification and therapy

Area of Science:

• Hematology
• Oncology
• Genetics

Background:

• Multiple myeloma (MM) is a plasma cell neoplasm affecting older adults, preceded by monoclonal gammopathy of undetermined significance and smouldering MM.
• MM is currently viewed as a single entity, but exhibits significant heterogeneity in clinical presentation, treatment response, and survival.
• This heterogeneity is linked to specific chromosomal abnormalities present in nearly all MM patients.

Purpose of the Study:

• To review current treatment approaches for multiple myeloma.
• To propose modifications to standard care based on underlying cytogenetic abnormalities.
• To enhance clinical benefit for specific MM patient subgroups through targeted therapies.

Main Methods:

• Review of current standard of care for multiple myeloma.
• Analysis of the role of primary and secondary cytogenetic abnormalities in MM.
• Identification of patient subgroups based on specific genetic alterations.

Main Results:

• MM exhibits diverse clinical behaviors driven by distinct cytogenetic abnormalities, including translocations (14q), trisomies (odd chromosomes), deletion (17p), and amplification (1q).
• These genetic alterations define non-overlapping MM disease entities with unique clinical characteristics.
• Subgroup classification based on cytogenetics is crucial for understanding disease behavior.

Conclusions:

• MM is a biologically diverse disease, not a single entity, necessitating subtype-specific treatment strategies.
• Tailoring treatments to the underlying cytogenetic profile of MM can improve patient outcomes.
• Further research into MM subtypes and targeted therapies holds promise for advancing care.